Alpha 2 Macroglobulin, Human Plasma, Fast Form recombinant protein
C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5, A2M, CPAMD5, FWP007
|Calculated MW||725 kDa (Homotetramer, Subunit size: 180 kDa)|
|Other Names||C3 and PZP-like alpha-2-macroglobulin domain-containing protein 5, A2M, CPAMD5, FWP007|
|Target/Specificity||Alpha 2 Macroglobulin|
|Application Notes||In water or aqueous buffer|
|Storage||-20°C; Lyophilized from 100 mM Na Phosphate, pH 7.2.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Alpha 2 Macroglobulin (A2M) is a plasma protease inhibitor which has been shown to exist in two forms. The Slow Form of A2M (S-A2M) is the form which possesses the ability to bind and inhibit proteases by a “trap” method. The Fast Form of A2M (F-A2M) is generated when S-A2M undergoes a conformational change due to either entrapment of a protease in the A2M bait region, or chemical cleavage of an internal thiol ester bond located near the bait region. F-A2M does not possess the ability to bind and inhibit protease activity. F-A2M is rapidly taken up by the liver, with a half-life of 2-4 minutes. In vivo, F-A2M typically represents only 0.17–0.7% of the total A2M in blood plasma of adults. The F-A2M plasma concentration is, however, increased in many disease states including pancreatitis, multiple sclerosis and sepsis. F-A2M has also been implicated in the inhibition of amyloid formation associated with Alzheimer’s disease and spongiform encephalopathy.
Kan C.-C.,et al.Proc. Natl. Acad. Sci. U.S.A. 82:2282-2286(1985).
Lin V.K.,et al.Prostate 63:299-308(2005).
Totoki Y.,et al.Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
Bechtel S.,et al.BMC Genomics 8:399-399(2007).
Scherer S.E.,et al.Nature 440:346-351(2006).
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.